Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$15.74
-2.3%
$19.17
$15.45
$33.31
$2.24B1.331.17 million shs302,191 shs
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$118.83
+0.2%
$121.99
$87.14
$127.57
$6.76B0.94264,663 shs92,394 shs
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$29.07
-1.1%
$36.28
$27.85
$59.10
$2.28B1.12688,570 shs460,055 shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$27.35
-3.8%
$27.71
$25.69
$77.14
$1.26B0.76536,682 shs169,133 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
+0.75%-7.09%-17.89%-5.84%-35.43%
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
+1.19%+0.81%-4.18%+2.99%+18.67%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
+1.38%-7.67%-12.97%-29.09%-50.02%
Omnicell, Inc. stock logo
OMCL
Omnicell
+0.89%+6.68%+1.79%-16.85%-54.42%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.7294 of 5 stars
3.51.00.04.72.52.50.0
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
4.034 of 5 stars
1.41.03.34.81.92.52.5
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
4.9199 of 5 stars
3.15.00.04.02.91.73.8
Omnicell, Inc. stock logo
OMCL
Omnicell
1.9716 of 5 stars
3.21.00.00.01.81.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.00
Buy$41.22161.89% Upside
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
2.80
Moderate Buy$123.604.01% Upside
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
2.22
Hold$44.8954.42% Upside
Omnicell, Inc. stock logo
OMCL
Omnicell
2.33
Hold$42.2054.30% Upside

Current Analyst Ratings

Latest ENSG, OMCL, DNLI, and IART Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/9/2024
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$70.00 ➝ $32.00
4/3/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$38.00
3/1/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$46.00 ➝ $41.00
2/29/2024
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$73.00 ➝ $50.00
2/29/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$55.00 ➝ $49.00
2/28/2024
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$105.00 ➝ $95.00
2/28/2024
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00
2/22/2024
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$105.00
2/9/2024
Omnicell, Inc. stock logo
OMCL
Omnicell
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $38.00
2/9/2024
Omnicell, Inc. stock logo
OMCL
Omnicell
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $26.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M6.79N/AN/A$7.42 per share2.12
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$3.73B1.81$5.83 per share20.40$26.42 per share4.50
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$1.54B1.48$4.85 per share6.00$20.31 per share1.43
Omnicell, Inc. stock logo
OMCL
Omnicell
$1.15B1.09$3.05 per share8.96$26.15 per share1.05

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$145.22M-$1.08N/AN/AN/A-36.51%-13.50%-11.38%5/13/2024 (Estimated)
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$209.40M$3.6632.4721.721.575.61%17.84%6.30%4/24/2024 (Estimated)
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$67.74M$0.8335.028.050.874.39%15.19%6.59%5/6/2024 (Confirmed)
Omnicell, Inc. stock logo
OMCL
Omnicell
-$20.37M-$0.45N/A75.97N/A-1.78%3.43%1.81%5/2/2024 (Confirmed)

Latest ENSG, OMCL, DNLI, and IART Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.55N/A-$0.55N/AN/AN/A  
5/2/2024N/A
Omnicell, Inc. stock logo
OMCL
Omnicell
-$0.0830N/A+$0.0830N/AN/AN/A  
2/28/202412/31/2023
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.90$0.89-$0.01$1.53$399.30 million$397.00 million    
2/27/2024Q4 2023
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.81-$0.86-$0.05-$0.86$3.38 millionN/A
2/8/2024Q4 2023
Omnicell, Inc. stock logo
OMCL
Omnicell
-$0.10$0.12+$0.22$0.56$256.00 million$258.85 million
2/1/2024Q4 2023
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$1.17$1.17N/A$1.96$975.13 million$980.38 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$0.240.20%+4.71%6.56%17 Years
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
N/AN/AN/AN/AN/A

Latest ENSG, OMCL, DNLI, and IART Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/22/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Quarterly$0.060.19%3/27/20243/31/20244/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
13.65
13.65
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.10
1.42
1.42
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
0.94
3.45
2.18
Omnicell, Inc. stock logo
OMCL
Omnicell
0.48
2.52
2.22

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
96.12%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
84.78%
Omnicell, Inc. stock logo
OMCL
Omnicell
97.70%

Insider Ownership

CompanyInsider Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
7.90%
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
3.90%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3.10%
Omnicell, Inc. stock logo
OMCL
Omnicell
2.64%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
445142.54 million131.28 millionOptionable
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
35,30056.90 million54.69 millionOptionable
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3,94678.60 million76.17 millionOptionable
Omnicell, Inc. stock logo
OMCL
Omnicell
3,65045.92 million44.71 millionOptionable

ENSG, OMCL, DNLI, and IART Headlines

SourceHeadline
Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of "Hold" from AnalystsOmnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of "Hold" from Analysts
americanbankingnews.com - April 23 at 2:20 AM
Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of "Hold" by BrokeragesOmnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of "Hold" by Brokerages
marketbeat.com - April 23 at 2:13 AM
Zacks Research Analysts Cut Earnings Estimates for Omnicell, Inc. (NASDAQ:OMCL)Zacks Research Analysts Cut Earnings Estimates for Omnicell, Inc. (NASDAQ:OMCL)
americanbankingnews.com - April 19 at 2:16 AM
Omnicell launches XT Amplify to enhance dispensing systemOmnicell launches XT Amplify to enhance dispensing system
investing.com - April 18 at 10:10 AM
Q2 2024 Earnings Forecast for Omnicell, Inc. (NASDAQ:OMCL) Issued By Zacks ResearchQ2 2024 Earnings Forecast for Omnicell, Inc. (NASDAQ:OMCL) Issued By Zacks Research
marketbeat.com - April 18 at 5:59 AM
Q3 2024 Earnings Forecast for Omnicell, Inc. Issued By Zacks Research (NASDAQ:OMCL)Q3 2024 Earnings Forecast for Omnicell, Inc. Issued By Zacks Research (NASDAQ:OMCL)
americanbankingnews.com - April 18 at 1:46 AM
Q3 2024 EPS Estimates for Omnicell, Inc. (NASDAQ:OMCL) Raised by AnalystQ3 2024 EPS Estimates for Omnicell, Inc. (NASDAQ:OMCL) Raised by Analyst
marketbeat.com - April 17 at 5:24 PM
Omnicell Announces XT AmplifyOmnicell Announces XT Amplify
businesswire.com - April 16 at 4:01 PM
Investors in Omnicell (NASDAQ:OMCL) have unfortunately lost 80% over the last three yearsInvestors in Omnicell (NASDAQ:OMCL) have unfortunately lost 80% over the last three years
finance.yahoo.com - April 14 at 3:02 PM
Sysdig Named 2024 Google Cloud Technology Partner of the Year for SecuritySysdig Named 2024 Google Cloud Technology Partner of the Year for Security
01net.it - April 10 at 7:43 PM
Omnicell (NASDAQ:OMCL) Stock Price Down 7%Omnicell (NASDAQ:OMCL) Stock Price Down 7%
marketbeat.com - April 10 at 12:57 PM
Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024
finance.yahoo.com - April 8 at 4:15 PM
Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024
businesswire.com - April 8 at 4:01 PM
Commit To Buy Omnicell At $15, Earn 5.6% Annualized Using OptionsCommit To Buy Omnicell At $15, Earn 5.6% Annualized Using Options
nasdaq.com - April 7 at 8:18 AM
Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by GAM Holding AGOmnicell, Inc. (NASDAQ:OMCL) Shares Sold by GAM Holding AG
marketbeat.com - April 3 at 7:23 PM
Vanguard Group Inc. Boosts Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)Vanguard Group Inc. Boosts Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)
marketbeat.com - March 30 at 4:09 AM
363,739 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Assenagon Asset Management S.A.363,739 Shares in Omnicell, Inc. (NASDAQ:OMCL) Acquired by Assenagon Asset Management S.A.
marketbeat.com - March 29 at 5:16 AM
Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of "Hold" from BrokeragesOmnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of "Hold" from Brokerages
marketbeat.com - March 29 at 2:14 AM
Trump Truth Social shares worth $58 as first trading day on Wall Street closesTrump Truth Social shares worth $58 as first trading day on Wall Street closes
msn.com - March 28 at 4:48 PM
3 Robotics Stocks That Could Soar as the Technology Advances3 Robotics Stocks That Could Soar as the Technology Advances
finance.yahoo.com - March 27 at 8:45 AM
Reasons for the Decline of Omnicell (OMCL)Reasons for the Decline of Omnicell (OMCL)
finance.yahoo.com - March 27 at 8:45 AM
Pacer Advisors Inc. Purchases 1,057,698 Shares of Omnicell, Inc. (NASDAQ:OMCL)Pacer Advisors Inc. Purchases 1,057,698 Shares of Omnicell, Inc. (NASDAQ:OMCL)
marketbeat.com - March 26 at 7:54 AM
Omnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor ForumOmnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum
businesswire.com - March 11 at 5:11 PM
Omnicell’s Steady Demand and Modest Revenue Projections Justify Hold RatingOmnicell’s Steady Demand and Modest Revenue Projections Justify Hold Rating
markets.businessinsider.com - March 1 at 1:57 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Denali Therapeutics logo

Denali Therapeutics

NASDAQ:DNLI
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
The Ensign Group logo

The Ensign Group

NASDAQ:ENSG
The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.
Integra LifeSciences logo

Integra LifeSciences

NASDAQ:IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Omnicell logo

Omnicell

NASDAQ:OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.